Cornerstone Pharmaceuticals has received US FDA clearance to initiate Phase I human clinical trials of the anticancer agent, CPI-613.

The trial, to be conducted at Wake Forest University Baptist Medical Center, will enrol patients with advanced hematologic malignancies, including eligible leukaemia and lymphoma patients as well as those with acute myeloid leukaemia.

Cornerstone and Wake Forest University collaborated previously to evaluate CPI-613 in a mouse model of acute myeloid leukaemia to help study treatment in humans.

CPI-613 is the lead candidate from Cornerstone’s Altered Energy Metabolism Directed technology platform that targets metabolic changes common to multiple cancers.